Today: 9 April 2026
Molina Healthcare stock rises again after Michael Burry touts insurer; Feb. 5 earnings in focus
31 December 2025
1 min read

Molina Healthcare stock rises again after Michael Burry touts insurer; Feb. 5 earnings in focus

NEW YORK, December 31, 2025, 10:30 ET — Regular session

  • Molina Healthcare shares rose about 2% in morning trading, outpacing a softer healthcare sector.
  • Buying followed fresh attention from investor Michael Burry, who compared Molina to Berkshire Hathaway’s Geico.
  • Molina set its fourth-quarter and full-year earnings release for Feb. 5 after the market close.

Molina Healthcare Inc shares were up 2.1% at $174.33 by 10:30 a.m. ET on Wednesday, after trading between $170.03 and $176.33 earlier in the session.

The move matters because Molina has been highly sensitive to shifts in sentiment after cutting its 2025 profit outlook in October on higher medical costs, particularly in its Affordable Care Act marketplace business. “Approximately half of our underperformance is driven by the Marketplace business,” CEO Joseph Zubretsky said at the time. Reuters

Investors are now looking to the company’s next update for signs that medical-cost trends are stabilizing and that pricing is catching up with claims. Molina said it will publish fourth-quarter and full-year 2025 results after the market closes on Feb. 5, 2026, and hold a conference call and webcast on Feb. 6. Business Wire

Buying also followed fresh attention from Michael Burry, the investor portrayed in “The Big Short,” who compared Molina to Berkshire Hathaway’s Geico and floated the idea of acquiring the insurer if he had the capital, Business Insider reported. Business Insider

The renewed focus comes as managed-care investors stay fixated on profitability drivers that can swing quickly, including the medical loss ratio — the share of premium revenue paid out in medical claims.

Molina’s mix spans Medicaid, Medicare and state marketplace plans, leaving results exposed to utilization trends and the pace at which state and federal reimbursement updates filter through.

The stock’s rise also stood out against broader weakness. The Health Care Select Sector SPDR Fund was down 0.2%, while the SPDR S&P 500 ETF Trust slipped 0.3%.

Managed-care peers were mixed. Centene was up about 0.4%, while UnitedHealth was down about 0.4%; Elevance and Humana were marginally higher.

Analysts remain cautious overall. Data compiled by MarketWatch show an average recommendation of “Hold” and an average target price of about $173 for Molina. MarketWatch

For traders, the near-term focus is whether the stock can hold above Tuesday’s close of $170.66 and stay near the top of Wednesday’s intraday range, rather than slipping back toward the day’s low.

Stock Market Today

  • Cloudflare Shares Drop 7.6% Following CEO Insider Sales
    April 9, 2026, 11:57 AM EDT. Cloudflare's (NYSE:NET) stock price fell 7.6% to $195.19 after CEO Matthew Prince sold large blocks of shares totaling over $22 million. The trades, executed under a pre-arranged Rule 10b5-1 plan, sharply cut the CEO's ownership by nearly 99% in one instance. Trading volume was down 79% from average. Despite the sell-off, Wall Street analysts remain optimistic with a consensus 'Moderate Buy' rating and an average price target around $233. Leading firms like Citigroup and BTIG have recently raised price targets, signaling confidence in Cloudflare's long-term prospects.

Latest article

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

9 April 2026
Palantir Technologies dropped about 7% Thursday after Michael Burry said Anthropic was overtaking it in enterprise AI, putting Palantir on track to lose $34 billion in market value. Anthropic reported its annualized revenue run rate had surged past $30 billion and launched new AI tools for businesses. Nearly one in four businesses on Ramp now pays for Anthropic, according to Ramp data. Palantir’s stock still trades at 395 times earnings.
Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

9 April 2026
Salesforce shares hit a new 52-week low Thursday, dropping 3.7% to $169.76 despite reporting 12% revenue growth and strong demand for its AI products. The broader software sector continued to slide, with the S&P 500 software and services index down about $1 trillion since January. Salesforce raised its buyback authorization to $50 billion and increased its dividend to 44 cents a share.
ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

9 April 2026
ServiceNow shares dropped 5.1% to $92.45 by 10:20 a.m. EDT Thursday, hitting a new 52-week low after analysts at Stifel, BTIG, and Goldman Sachs cut price targets citing weak federal spending and limited 2026 growth. The company announced it will integrate AI, data, security, and governance into all products ahead of first-quarter results due April 22.
SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

Tesla revives cheaper EV bet with compact SUV plan in China after sales strain

9 April 2026
Tesla is developing a smaller, cheaper electric SUV to be built first in Shanghai, sources said. The new model would cost less than the Model 3 and be smaller than the Model Y. Tesla produced 408,386 vehicles but delivered only 358,023 in Q1, as U.S. demand weakened and competition increased. Shares fell 0.8% Thursday.
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade
Previous Story

Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

Polestar stock jumps as BBVA discloses 8.4% stake and Geely backstop details surface
Next Story

Polestar stock jumps as BBVA discloses 8.4% stake and Geely backstop details surface

Go toTop